Ieq Capital LLC Buys Shares of 66,567 Vir Biotechnology, Inc. $VIR

Ieq Capital LLC purchased a new position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 66,567 shares of the company’s stock, valued at approximately $678,000.

A number of other hedge funds also recently modified their holdings of VIR. BlackRock Inc. purchased a new position in Vir Biotechnology in the second quarter valued at approximately $210,712,000. GSK plc bought a new stake in shares of Vir Biotechnology in the fourth quarter valued at $51,562,000. ADAR1 Capital Management LLC bought a new stake in shares of Vir Biotechnology in the first quarter valued at $24,593,000. Pictet Asset Management Holding SA lifted its position in shares of Vir Biotechnology by 10,878.9% during the 1st quarter. Pictet Asset Management Holding SA now owns 1,480,828 shares of the company’s stock valued at $13,268,000 after buying an additional 1,467,340 shares during the last quarter. Finally, Balyasny Asset Management L.P. bought a new position in shares of Vir Biotechnology during the 4th quarter worth $8,252,000. Institutional investors own 65.32% of the company’s stock.

Wall Street Analysts Forecast Growth

VIR has been the topic of a number of research reports. Leerink Partners boosted their price objective on Vir Biotechnology from $20.00 to $21.00 and gave the company an “outperform” rating in a research note on Wednesday, June 3rd. Wall Street Zen upgraded shares of Vir Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Wednesday, July 8th. HC Wainwright reissued a “buy” rating on shares of Vir Biotechnology in a research report on Monday, August 10th. Finally, Morgan Stanley set a $25.00 price target on shares of Vir Biotechnology in a research note on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Vir Biotechnology presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.57.

Vir Biotechnology Price Performance

Shares of NASDAQ:VIR opened at $11.31 on Friday. The firm has a fifty day moving average price of $9.56 and a two-hundred day moving average price of $9.29. The company has a market cap of $1.91 billion, a price-to-earnings ratio of -6.08 and a beta of 1.66. Vir Biotechnology, Inc. has a one year low of $4.75 and a one year high of $11.66.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.47 earnings per share for the quarter, topping the consensus estimate of $0.33 by $0.14. Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 29.99%. The firm had revenue of $238.95 million for the quarter, compared to analysts’ expectations of $135.88 million. During the same quarter in the prior year, the firm posted ($0.80) earnings per share. The business’s quarterly revenue was up 19582.5% on a year-over-year basis. Equities research analysts expect that Vir Biotechnology, Inc. will post -1.84 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Janet Napolitano sold 3,200 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $9.45, for a total transaction of $30,240.00. Following the completion of the transaction, the director directly owned 21,216 shares in the company, valued at $200,491.20. The trade was a 13.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.90% of the stock is currently owned by insiders.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical?stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell?based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID?19, HIV, hepatitis B, and tuberculosis.